APOE and amyloidosis: These recommendations highlight the need for careful patient selection, including the presence of amyloid pathology; the exclusion of patients at high risk of developing amyloid‐related imaging abnormalities (ARIA), such as those with cerebrovascular disease; recommendations for apolipoprotein E ε4 (APOE ε4) genotyping to assess ARIA risk; and monitoring of asymptomatic ARIA using serial magnetic resonance imaging.14, 15